Hemp Stocks

  • Aurora Cannabis weighs on sector after BofA downgrade highlights cash burn

    [Blocked Image: https://s.yimg.com/ny/api/res/1.2/JTT4wS6ixv_efq7Og1RJjQ--~A/YXBwaWQ9aGlnaGxhbmRlcjtzbT0xO3c9ODQ7aD04NDtpbD1wbGFuZQ--/http://l.yimg.com/os/publish-images/finance/2016-03-04/b1d18a20-e20d-11e5-99a3-0b72938c288d_MWLOGO.jpg]

    Ciara Linnane


    Aurora Cannabis shares tumbled Thursday to pull the overall sector lower, after BofA Merrill Lynch downgraded the stock on concerns about its cash burn.


  • ...endlich mal erfreulich

    9.31+2.41 (+34.93%)

    As of 12:28PM EDT. Market open.

    Marijuana Stock Aphria Is Soaring After Earnings Show It Has Turned Itself Around


    Bill Alpert

    Updated Aug. 2, 2019 12:19 pm ET / Original Aug. 2, 2019 10:57 am ET

    [Blocked Image: https://images.barrons.com/im-95198?width=620&size=1.5]

    Photograph by Kimzy Nanney

    Canadian cannabis leader Aphria executed a sharp turnaround in its May quarter sales, avoiding the steep losses suffered in the similar stretch by rival Canopy Growth .

    The Leamington, Ontario-based company said late Thursday that quarterly revenue jumped 75% from the February quarter, when founder and chief executive Vic Neufeld stepped down after shortsellers pointed out self-interested deals by Aphria executives.....


    leider habe ich Aphria nicht mehr

  • Aurora Info

    Auch erfreulich:

    Aurora Cannabis Provides Corporate Update for the Fourth Quarter of Fiscal 2019

    EDMONTON, Aug. 6, 2019 - Aurora Cannabis Inc. ("Aurora" or the "Company") (NYSE | TSX: ACB), the Canadian company defining the future of cannabis worldwide, today provided a corporate update on selected financial metrics for the fourth quarter of the Company's Fiscal 2019 ("Q4 2019") period ended June 30, 2019. This reiteration of guidance and clarification of operations is intended to update our investors as Aurora continues to demonstrate leadership in transparency and disclosure as the industry navigates throughs periods of volatility. Full results will be published prior to September 15, 2019, details for which will be provided in advance.

    Based on a preliminary (unaudited) review, the Company anticipates net revenues for the quarter ended June 30, 2019of between $100 million and $107 million (net of excise taxes), compared to $19.1 million in the period ended June 30, 2018, and compared to $65.1 million for the previous quarter ended March 31, 2019. Fiscal Q4 2019 net cannabis revenue is expected to be between $90 million and $95 million, with growth anticipated across all key business segments including medical, both Canadian and international, and consumer markets. The Company anticipates total net revenues for the fiscal year ended June 30, 2019 to be between $249 million - $256 million. The Company expects to report that production available for sale for Q4 2019 will be at the upper end of the range between 25,000 kg and 30,000 kg, ahead of previous guidance of 25,000 kgs.

    These production and revenue estimates reflect strong delivery against corporate Key Performance Indicators ("KPIs"), the financial metrics the Company uses to evaluate the business on a day-to-day basis. The Company also expects to report sequential quarterly improvements in these KPIs, in particular: gross margins, kilograms of cannabis sold and cash costs per gram produced. The Company continues to track toward positive adjusted EBITDA, and in particular adjusted EBITDA from cannabis operations.

    From the beginning, the Company's core philosophy of "purpose-built facilities" has focused on high quality cultivation of medical grade cannabis globally. This approach is validated by material growth in production and revenue and continued improvement in the above KPIs. Aurora's management team and Board of Directors continue to drive a culture rooted in quality, transparency, and regulatory compliance. Aurora has grown both organically and through acquisitions of companies with shared visions, and today this culture is ingrained in Aurora's over 2,500 employees across the globe.

    "Our Q4 2019 guidance highlights Aurora's continued leadership," said Terry Booth, CEO of Aurora. "We set out to be best-in-class cultivators, and through carefully evaluated acquisitions, that vision continues to drive exceptional results today. We are the leader in cultivation capacity, production available for sale and revenues for cannabis in the Canadian medical and consumer markets. We continue to lead the build out of European and other international medical cannabis markets. Our success to date comes from a focus on quality, regulatory compliance, appropriate Board of Directors oversight, and delivering a profitable, low risk and sustainable business for our shareholders."

    The preliminary estimated financial results and other data for the three months ended June 30, 2019 set forth above are subject to the completion of the Company's financial closing procedures. This data has been prepared by, and is the responsibility of, the Company's management. Aurora's independent registered public accounting firm, KPMG LLP, is in the process of performing year-end audit procedures with respect to the accompanying preliminary financial results and other data, and accordingly does not express an opinion or any other form of assurance with respect thereto. The Company currently expects that its final results of operations and other data will be consistent with the estimates set forth above, but such estimates are preliminary and Aurora's actual results of operations and other data could differ materially from these estimates due to the completion of its fiscal year-end audit procedures, final adjustments, and other developments that may arise between now and the time such annual audited consolidated financial statements for the twelve months ended June 30, 2019 are released.

    The Company defines adjusted EBITDA as net income (loss) excluding interest income (expense), accretion, income taxes, depreciation, amortization, changes in fair value of inventory sold, changes in fair value of biological assets, share-based compensation, changes in fair value of financial instruments, gains and losses on deemed disposal, and non-cash impairment of equity investments, goodwill and intangible assets. Adjusted EBITDA from cannabis operations is defined as adjusted EBITDA for the Company's business units engaged in the production and sale of cannabis and legal derivatives thereof and excludes non-cannabis-related business units or operations.

    About Aurora

    Headquartered in Edmonton, Alberta, Canada with funded capacity in excess of 625,000 kg per annum and sales and operations in 25 countries across five continents, Aurora is one of the world's largest and leading cannabis companies. Aurora is vertically integrated and horizontally diversified across every key segment of the value chain, from facility engineering and design to cannabis breeding and genetics research, cannabis and hemp production, derivatives, high value-add product development, home cultivation, wholesale and retail distribution.

    Highly differentiated from its peers, Aurora has established a uniquely advanced, consistent and efficient production strategy, based on purpose-built facilities that integrate leading-edge technologies across all processes, defined by extensive automation and customization, resulting in the massive scale production of high-quality consistent product. Designed to be replicable and scalable globally, our production facilities are designed to produce cannabis at significant scale, with high quality, industry-leading yields, and low-per gram production costs. Each of Aurora's facilities is built to meet European Union Good Manufacturing Practices ("EU GMP") standards. Certification has been granted to Aurora's first production facility in Mountain View County, the MedReleaf Markham facility, and its wholly owned European medical cannabis distributor Aurora Deutschland. All Aurora facilities are designed and built to the EU GMP standard.

    In addition to the Company's rapid organic growth and strong execution on strategic M&A, which to date includes 17 wholly owned subsidiary companies – MedReleaf, CanvasRX, Peloton Pharmaceutical, Aurora Deutschland, H2 Biopharma, BC Northern Lights, Larssen Greenhouses, CanniMed Therapeutics, Anandia, HotHouse Consulting, MED Colombia, Agropro, Borela, ICC Labs, Whistler, and Chemi Pharmaceutical – Aurora is distinguished by its reputation as a partner and employer of choice in the global cannabis sector, having invested in and established strategic partnerships with a range of leading innovators, including: Radient Technologies Inc. (TSXV: RTI), Hempco Food and Fiber Inc. (TSXV: HEMP), Cann Group Ltd. (ASX: CAN), Micron Waste Technologies Inc. (CSE: MWM), Choom Holdings Inc. (CSE: CHOO), CTT Pharmaceuticals (OTCC: CTTH), Alcanna Inc. (TSX: CLIQ), High Tide Inc. (CSE: HITI), EnWave Corporation (TSXV: ENW), Capcium Inc. (private), Evio Beauty Group (private), and Wagner Dimas (private).

    Aurora's Common Shares trade on the TSX and NYSE under the symbol "ACB", and is a constituent of the S&P/TSX Composite Index.

    For more information about Aurora, please visit our investor website, investor.auroramj.com

    Terry Booth, CEO
    Aurora Cannabis Inc.

  • Canopy Growth, world’s largest pot company, lost $1 billion in three months

    Max A. Cherney

    MarketWatchAugust 15, 2019

    Canopy Growth Corp. reported a C$1.28 billion quarterly loss late Wednesday and missed analyst estimates for revenue, sending shares down 10% in after-hours trading. The world's largest cannabis company by market value, Canopy Growth (CGC)(CA:WEED) reported fiscal first-quarter net losses of C$1.28 billion, or C$3.70 a share, compared with losses of C$91 million, or 40 cents a share, in the year-ago period. The more than $1 billion loss was due to the company extinguishing warrants related to the Constellation Brands Inc. (STZ) investment.

    Continue reading


    ...ja hätte...wenn...usw. ich jedenfalls sitze mittlerweile auf zünftigen Verlusten obwohl ich sehr abgebaut habe....

  • Aurora Cannabis Stock Slides As This 'Significant Ask' Looms; Marijuana Stocks Rise

    [Blocked Image: https://s.yimg.com/it/api/res/1.2/j.nDBts3aNj90RQKYwb3wA--~A/YXBwaWQ9eW5ld3M7c209MTt3PTg0O2g9ODQ-/https://media-mbst-pub-ue1.s3.amazonaws.com/creatr-uploaded-images/2019-07/441c3740-a7e5-11e9-a77a-98f42651650f]



    Investor's Business DailySeptember 16, 2019

    [Blocked Image: https://s.yimg.com/it/api/res/1.2/y28Injflc6IUlD0_1aotYA--~A/YXBwaWQ9eW5ld3M7c209MTt3PTgwMA--/https://media.zenfs.com/en/ibd.com/a7d85f6100dbd6e9abbf678d652aee08]

    Aurora Cannabis Stock Slides As This 'Significant Ask' Looms; Marijuana Stocks Rise

    Aurora Cannabis could have to make a "significant ask" of investors to fund aggressive global growth ambitions, Stifel said in downgrading shares of the Canadian pot producer, adding to analysts' concerns about the company's cash and sales prospects. Aurora Cannabis stock fell, while other marijuana stocks moved higher. Stifel, in a research note dated Sunday, downgraded Aurora Cannabis stock to sell, after Aurora's quarterly results disappointed Wall Street last week.

    Continue reading

    ....ist wohl bald ein penny-stock (grrrrrr......)

  • Info

    Heute gesehen: *dirol*

    Das US-Repräsentantenhaus will Cannabis-Unternehmern den Zugang zum Bankensektor erleichtern. Die Abgeordneten stimmten mit einer deutlichen Mehrheit für ein entsprechendes Gesetz. Hintergrund: Die Branche hat Schwierigkeiten ihre legal erwirtschafteten Einnahmen anzulegen, da das US-Bundesrecht Cannabis weiterhin als gefährliche Droge einstuft, obwohl der Anbau und der Konsum von Marihuana in zahlreichen US-Bundesstaaten bereits legalisiert wurde.



  • Obige Info

    *biggrin* *dirol*

    Danke @ Selector, das sind gute News. Habe auch grad noch was gesehen hierüber:

    Die Aktien der Cannabis-Unternehmen können endlich einmal wieder mit größeren Kursgewinnen aufwarten. Die Aktie von Canopy Growth steigt am Donnerstagmorgen 4,6 Prozent, Aurora Cannabis legt 4,1 Prozent zu, Aphria 3,7 Prozent und Cronos 3,4 Prozent. Grund sind positive News aus den USA, dem wichtigsten Cannabis-Markt der Welt.

    Created with Highcharts 7.1.2Aurora CannabisNov '18Jan '19Mär '19Mai '19Jul '19Sep '1934567891011

    Aurora Cannabis (WKN: A12GS7)

    Das US-Repräsentantenhaus stimmte mit überwältigender Mehrheit für die Verabschiedung des SAFE Banking Acts. Dieser ermöglicht staatlich zugelassenen Cannabis-Firmen den uneingeschränkten Zugang zu Banken und anderen Finanzdienstleistungen. Zudem können Verbraucher zukünftig beim Kauf von Cannabis Kredit- und Debitkarten verwenden. Bislang liefen Banken Gefahr, strafrechtlich verfolgt zu werden.

    [Blocked Image: https://images.boersenmedien.com/images/0f24d29d-0272-4828-a957-e5f517737ed9.jpg?w=1000]

    Cannabis ist in den USA auf Bundesebene noch immer illegal, egal ob man nur anbaut oder kifft. 33 der 50 US-Bundesstaaten sowie der Bundesdistrikt Washington, D.C. haben den Gebrauch von Cannabis als Arzneimittel aber zumindest auf Staatenebene legalisiert. In 11 der 50 amerikanischen Bundesstaaten ist Cannabis auch als Genussmittel für Personen ab 21 Jahren erlaubt. Legal kiffen kann man derzeit in Alaska, Colorado, Illinois, Kalifornien, Maine, Massachusetts, Michigan, Nevada, Oregon, Vermont und Washington (Bundesstaat). Außerdem hat der Bundesdistrikt und Regierungssitz Washington D.C. den privaten Gebrauch von Cannabis legalisiert.

    Created with Highcharts 7.1.2Canopy GrowthNov '18Jan '19Mär '19Mai '19Jul '19Sep '191520253035404550

    Canopy Growth (WKN: A140QA)

    Positive News kommen auch aus Australien. In der Hauptstadt Canberra ist es ab dem kommenden Jahr erlaubt, Cannabis zu besitzen, zu konsumieren und anzubauen. Das entsprechende Gesetz wurde nun verabschiedet. Ab dem 31. Januar dürfen alle Über-18-Jährigen bis zu 50 Gramm Cannabis besitzen.

    Noch sind die Aktien der Cannabis-Unternehmen charttechnisch massiv angeschlagen. Die jüngsten News sind aber ein klares positives Signal. In den kommenden Monaten und Jahren könnten weitere wichtige Legalisierungsschritte folgen. Ein Paukenschlag wäre natürlich die Komplettlegalisierung in den USA. Anleger sollten den Markt genau beobachten. Dreht die Stimmung am Cannabis-Markt ins positive könnten die stark überverkauften Aktien wie Aurora Cannabis und Canopy Growth schnell wieder deutlich zulegen.




  • @ Lorenz zu Aurora etc.

    @ Lorenz.

    Danke dir auch. Wie du ja weisst sind die Kurse bei CGC und ACB recht stark zurückgekommen. Dies erneut, seit so ein Aanal-Depp um den 20. Sept. rum was von KE gefaselt hat. Da siehst du, was sowas ausmacht. Offiziell ist überhaupt nichts dergleichen geplant. Bei ACB sollen noch die Q1-Zahlen kommen, gemäss Bank am 28. Oktober. Habe ich grad mal gesehen. Nun denn, man sagt ja 'reden ist Silber und schweigen ist Gold'. Also, ich bin nun schön ruhig. *dirol*

  • Business

    Cannabis Short Sellers Bank $200M In Two Days

    Wayne Duggan

    BenzingaOctober 1, 2019

    [Blocked Image: https://s.yimg.com/it/api/res/1.2/3X4WRbeD.q2Mb8MEeDqb1g--~A/YXBwaWQ9eW5ld3M7c209MTt3PTYwMDtoPTQwMDtpbD1wbGFuZQ--/https://cdn1.benzinga.com/files/imagecache/600x400xUP/images/story/2012/cannabis-1382955_1920_52.jpg]

    It’s been a brutal year for cannabis investors, with the ETF MANAGERS TR/TIERRA XP LATIN AME (NYSE: MJ) down another 6.2% this week following a Bank of America downgrade of Canopy Growth Corp (NYSE: CGC) last week. Canopy carries one of the largest short positions in the cannabis group, but the stock’s dive has dragged down its cannabis peers as well.

    Short sellers have aggressively piled into the cannabis space in 2019, with short interest up 55% this year to $4.5 billion....

    ....Here are the five largest cannabis short positions following Monday’s volatile session:

    • Canopy Growth - $1.20 billion short interest.
    • Aurora Cannabis - $759.5 million short interest.
    • GW Pharmaceuticals PLC- ADR (NASDAQ: GWPH) - $459.4 million short interest.
    • Cronos Group Inc (NASDAQ: CRON) - $420.7 million short interest.

    Benzinga's Take.....


    ....ich hoffe sehr die bekommen noch zünftig auf die Nase....

  • Marijuana Stocks Are Sinking After Canada’s Hexo Issues a Bleak Outlook

    By Connor Smith

    Oct. 10, 2019 12:34 pm ET

    [Blocked Image: https://images.barrons.com/im-115688?width=620&size=1.5]

    Jay Stonne

    Canadian marijuana stocks were getting slammed on Thursday, few more so than Hexo Corp. , which had lost nearly a quarter of its value by midday.

    Hexo stock (ticker: HEXO) fell after the company said it expects fiscal fourth-quarter net revenue of between C$14.5 million (US$10.9 million) and C$16.5 million—well below previous estimates of about C$26 million. The company also withdrew its outlook for the new fiscal year.

    The company chalked up the disappointing performance to slower than expected store rollouts in major markets, as well as a delay in government approval for cannabis derivative products such as vapes and edibles—both industrywide concerns.

    “While we are disappointed with these results, we are making significant changes to our sales and operations strategy to drive future results,” CEO Sebastien St-Louis said in a statement. He said the company has begun refocusing on high-selling strains of pot. The company is also placing a “greater focus on profitability” and evaluating ways to be more efficient....

    .....Hexo shares were down 21% to $2.90 Thursday afternoon. Rival Canopy Growth (CGC) was down 8% to $20.98. Tilray (TLRY) stock fell 9.9% to $21.50, while Aphria (APHA) stock was down 8% to $4.96. Aurora Cannabis (ACB) was down 4.9% to $3.91. The S&P 500 was up 0.6%....


    ....hätte nie gedacht, dass ich mit diesen Aktien meine grössten Verluste habe....

  • Are These Marijuana Stocks A Good Buy Now? Look Past The Hype

    [Blocked Image: https://s.yimg.com/ny/api/res/1.2/C3lsSYLgi7PuYPwGJsZ0LQ--~A/YXBwaWQ9aGlnaGxhbmRlcjtzbT0xO3c9ODQ7aD04NA--/https://media-mbst-pub-ue1.s3.amazonaws.com/creatr-uploaded-images/2019-07/441c3740-a7e5-11e9-a77a-98f42651650f]


    Investor's Business DailyNovember 15, 2019

    Are These Marijuana Stocks A Good Buy Now? Look Past The Hype


    Are marijuana stocks on U.S. exchanges a good buy now? The marijuana industry gets a lot of hype, but look past the smoke and analyze pot stocks on their fundamentals and technicals.....


    Hier wird sehr umfassend informiert - ich scheine allein zu sein seit alles bergab geht...

  • Ist mir unverständlich. Hatte mal schöne gewinne und nun tief im minus. Eigentlich sind es kaufkurse. Aber eben. Ich bin breiter abgestützt mit dem horizon marijuana life science etf. Dieser war schon auf etwa 25cad und nun noch unter 9...werde einfach weiter warten und wenn es noch weiter sinken sollte dazukaufe. Industrie hat potential. Was haltet ihr von diesem etf? Zahlt übrigens auch schöne dividenden. Wenn mal ruhe hinein kommt und die shortseller weg sind, geht es schnell vom 9 wiedervauf 20 cad.

  • etf @ Paddington

    In diesem etf bin ich auch drin mit dem Gedanken breiter abgestützt zu sein ---> Resultat fast 50% Verlust. Das Dumme an solchen

    Verlusten ist um wieder eben zu sein muss das Teil 100% steigen - aufwärts ist immer viel mühsamer. Hemp Stocks kaufte ich unter

    anderem weil sie mir dieses Geschäft um vieles lieber ist als die grossen Multis mit ihrer Ausbeute in Dritte Welt Ländern, Waffen Industrie,

    Chemie und Pharma mit Ihrer Schädigung der Umwelt und der Patienten usw. usw.

    Werde drauf hocken bleiben *YES*

  • CGC / Aurora

    Nun, bei CGC könnte ich mir einen 50%-Kursanstieg gut vorstellen (Chart), zudem bringen die ihre Zahlen schon im Februar (Q3). Ev. noch etwas warten auf noch günstigere Kurse während der Feiertage? Allerdings, meine ich, wer Mut hat kann schon mal, ich sehe sowas wie ein Kaufsignal.

    Bei Aurora würde ich noch zuwarten. ein Anstieg bis ca. CAD$ 5.- liegt auch da drin, nur, da müsste mal erst ein etwas besseres Ergebnis gebracht werden.